Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Short-Term Debt
Aquestive Therapeutics Inc
Short-Term Debt Peer Comparison
Competitive Short-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Short-Term Debt
$6.3B
|
CAGR 3-Years
176%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Short-Term Debt
$3.3B
|
CAGR 3-Years
129%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Short-Term Debt
$7.2B
|
CAGR 3-Years
120%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eli Lilly and Co
NYSE:LLY
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Aquestive Therapeutics Inc's Short-Term Debt?
Short-Term Debt
0
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Short-Term Debt amounts to 0 USD.